The pharmaco-economics of peri-operative statin therapy

被引：21

作者：

Biccard, BM ^{[1
]}

Sear, JW ^{[1
]}

Foëx, P ^{[1
]}

机构：

[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England

来源：

ANAESTHESIA | 2005年 / 60卷 / 11期

关键词：

D O I：

10.1111/j.1365-2044.2005.04371.x

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

We analysed the pharmaco-economics of the prospective peri-operative studies of statin administration for major elective vascular surgery, using the NHS reference costs for 2004. This analysis suggests that peri-operative statin therapy for patients undergoing vascular surgery may present the most cost-effective use of statin therapy yet described, with a number-needed-to-treat of 15 and almost 60% of the total cost of atorvastatin therapy recovered through a reduction in peri-operative adverse events.

引用

页码：1059 / 1063

页数：5

共 41 条

[1]

[Anonymous], 2002, JAMA

[2] Beneficial effects of Pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study) [J].

Arntz, HR ;

Agrawal, R ;

Wunderlich, W ;

Schnitzer, L ;

Stern, R ;

Fischer, F ;

Schultheiss, HP .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (12) :1293-1298

[3] Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study [J].

Aronow, HD ;

Topol, EJ ;

Roe, MT ;

Houghtaling, PL ;

Wolski, KE ;

Lincoff, AM ;

Harrington, RA ;

Califf, RM ;

Ohman, EM ;

Kleiman, NS ;

Keltai, M ;

Wilcox, RG ;

Vahanian, A ;

Armstrong, PW ;

Lauer, MS .

LANCET, 2001, 357 (9262) :1063-1068

[4] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Mercouris, BR ;

Athyrou, VV ;

Symeonidis, AN ;

Basayannis, EO ;

Demitriadis, DS ;

Kontopoulos, AG .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228

[5]

*BMA, 2005, BRIT NAT FORM

[6] A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom [J].

Buller, N ;

Gillen, D ;

Casciano, R ;

Doyle, J ;

Wilson, K .

PHARMACOECONOMICS, 2003, 21 (Suppl 1) :25-32

[7] Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction [J].

Bybee, KA ;

Wright, RS ;

Williams, BA ;

Murphy, JG ;

Holmes, DR ;

Kopecky, SL .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :771-+

[8] Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].

Cannon, CP ;

Braunwald, E ;

McCabe, CH ;

Rader, DJ ;

Rouleau, JL ;

Belder, R ;

Joyal, SV ;

Hill, KA ;

Pfeffer, MA ;

Skene, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504

[9] LONG-TERM PROGNOSIS AFTER PERIOPERATIVE CARDIAC COMPLICATIONS [J].

CHARLSON, M ;

PETERSON, J ;

SZATROWSKI, TP ;

MACKENZIE, R ;

GOLD, J .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (12) :1389-1400

[10]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

← 1 2 3 4 5 →